Scientists at EPFL have developed EMBER, a tool integrating breast cancer transcriptomic data to enhance diagnosis and treatment precision.
- EMBER is a computational tool developed by scientists at EPFL to enhance breast cancer diagnosis and treatment by integrating transcriptomic data from multiple databases.
- Traditional cancer subtyping methods using histological staining are being revolutionized by high-throughput transcriptomic profiling, which analyzes gene activity in cancer cells.
- EMBER uses RNA sequencing data from over 11,000 breast cancer transcriptomes to predict cancer subtypes on a single-sample basis and improve therapy response predictions.
- The tool was validated using independent patient cohorts and clinical trial data, showcasing its ability to accurately predict responses to endocrine therapy and identify key biological pathways.
- EMBER offers a unified space for breast cancer transcriptomic data, allowing for more personalized treatment plans, better outcomes, and potential integration of RNA sequencing into standard diagnostic practices.
Source link
Oncology